<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cellular reprogramming of somatic cells to patient-specific induced pluripotent stem cells (iPSCs) enables in vitro modelling of human <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic disorders</z:e> for pathogenic investigations and therapeutic screens </plain></SENT>
<SENT sid="1" pm="."><plain>However, using iPSC-derived cardiomyocytes (iPSC-CMs) to model an <z:hpo ids='HP_0003581'>adult-onset</z:hpo> <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> remains challenging owing to the uncertainty regarding the ability of relatively immature iPSC-CMs to fully recapitulate <z:e sem="disease" ids="C0277562" disease_type="Disease or Syndrome" abbrv="">adult disease</z:e> phenotypes </plain></SENT>
<SENT sid="2" pm="."><plain>Arrhythmogenic right ventricular <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> (ARVD/C) is an inherited <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> characterized by pathological <z:mpath ids='MPATH_591'>fatty infiltration</z:mpath> and cardiomyocyte loss predominantly in the right ventricle, which is associated with life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Over 50% of affected individuals have desmosome gene mutations, most commonly in PKP2, encoding plakophilin-2 (ref </plain></SENT>
<SENT sid="4" pm="."><plain>9) </plain></SENT>
<SENT sid="5" pm="."><plain>The median age at presentation of ARVD/C is 26 years </plain></SENT>
<SENT sid="6" pm="."><plain>We used previously published methods to generate iPSC lines from fibroblasts of two patients with ARVD/C and PKP2 mutations </plain></SENT>
<SENT sid="7" pm="."><plain>Mutant PKP2 iPSC-CMs demonstrate abnormal plakoglobin nuclear translocation and decreased β-catenin activity in cardiogenic conditions; yet, these abnormal features are insufficient to reproduce the pathological phenotypes of ARVD/C in standard cardiogenic conditions </plain></SENT>
<SENT sid="8" pm="."><plain>Here we show that induction of adult-like metabolic energetics from an embryonic/glycolytic state and abnormal peroxisome proliferator-activated receptor gamma (PPAR-γ) activation underlie the pathogenesis of ARVD/C </plain></SENT>
<SENT sid="9" pm="."><plain>By co-activating <z:mpath ids='MPATH_458'>normal</z:mpath> PPAR-alpha-dependent metabolism and abnormal PPAR-γ pathway in beating embryoid bodies (EBs) with defined media, we established an efficient ARVD/C in vitro model within 2 months </plain></SENT>
<SENT sid="10" pm="."><plain>This model manifests exaggerated lipogenesis and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in mutant PKP2 iPSC-CMs </plain></SENT>
<SENT sid="11" pm="."><plain>iPSC-CMs with a homozygous PKP2 mutation also had calcium-handling deficits </plain></SENT>
<SENT sid="12" pm="."><plain>Our study is the first to demonstrate that induction of adult-like metabolism has a critical role in establishing an <z:hpo ids='HP_0003581'>adult-onset</z:hpo> <z:e sem="disease" ids="C0684309" disease_type="Experimental Model of Disease" abbrv="">disease model</z:e> using patient-specific iPSCs </plain></SENT>
<SENT sid="13" pm="."><plain>Using this model, we revealed crucial pathogenic insights that metabolic derangement in adult-like metabolic milieu underlies ARVD/C pathologies, enabling us to propose novel disease-modifying therapeutic strategies </plain></SENT>
</text></document>